| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1046/J.1537-2995.2003.00483.X |
| P698 | PubMed publication ID | 12919437 |
| P2093 | author name string | Rebecca Cardigan | |
| Chris V Prowse | |||
| Lorna M Williamson | |||
| P2860 | cites work | Photooxidation of fibrinogen in the presence of methylene blue and its effect on polymerization | Q50951982 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1322-1329 | |
| P577 | publication date | 2003-09-01 | |
| P1433 | published in | Transfusion | Q15758500 |
| P1476 | title | Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety? | |
| P478 | volume | 43 |
| Q83232961 | 4 Plasma for Therapeutic Use |
| Q50473987 | A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment. |
| Q37776318 | A comparison of methods of pathogen inactivation of FFP |
| Q37119689 | A study of the quantity of some stable and labile coagulation factors in fresh-frozen plasma produced from whole blood stored for 24 hours in Iran |
| Q92586213 | Antimicrobial blue light for decontamination of platelets during storage |
| Q42146633 | Challenge study of the pathogen reduction capacity of the THERAFLEX MB-Plasma technology |
| Q34777948 | Chemical and biological mechanisms of pathogen reduction technologies |
| Q33368173 | Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light |
| Q46978173 | Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen |
| Q34310415 | Component pathogen inactivation: a critical review |
| Q50439879 | Detection of nucleic acid lesions during photochemical inactivation of RNA viruses by treatment with methylene blue and light using real-time PCR. |
| Q52565814 | Efficacy and safety of methylene blue in the treatment of malaria: a systematic review. |
| Q40335637 | Fiber based pathogen photoinactivating system |
| Q37201179 | Fresh-frozen plasma, pathogen-reduced single-donor plasma or bio-pharmaceutical plasma? |
| Q26741073 | Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use |
| Q41940150 | High absolute bioavailability of methylene blue given as an aqueous oral formulation |
| Q59348963 | Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light, respectively |
| Q47340240 | Inactivation of bacteria in plasma |
| Q35567582 | Inactivation of model viruses suspended in fresh frozen plasma using novel methylene blue based device |
| Q84316297 | Inactivation of three emerging viruses – severe acute respiratory syndrome coronavirus, Crimean–Congo haemorrhagic fever virus and Nipah virus – in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light |
| Q33396311 | Main Properties of the THERAFLEX MB-Plasma System for Pathogen Reduction |
| Q96813845 | Methylene blue-treated plasma, versus quarantine fresh frozen plasma, for acute thrombotic thrombocytopenic purpura treatment: Comparison between centres and critical review on longitudinal data |
| Q46379566 | Paired analysis of plasma proteins and coagulant capacity after treatment with three methods of pathogen reduction. |
| Q36044573 | Pathogen inactivation technology: cleansing the blood supply |
| Q37013124 | Pathogen inactivation: making decisions about new technologies. Report of a consensus conference |
| Q37207560 | Pathogen reduction of blood components |
| Q41453112 | Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function |
| Q37811141 | Photodynamic Treatment: A New Efficient Alternative for Surface Sanitation |
| Q43369374 | Photodynamic treatment: a novel method for sanitation of food handling and food processing surfaces |
| Q33401173 | Plasma components: properties, differences, and uses |
| Q30460718 | Prospects for a novel ultrashort pulsed laser technology for pathogen inactivation |
| Q50787426 | Protein stability of previously frozen plasma, riboflavin and UV light-treated, refrozen and stored for up to 2 years at -30 °C. |
| Q50469599 | Quality and safety of fresh-frozen plasma inactivated and leucoreduced with the Theraflex methylene blue system including the Blueflex filter: 5 years' experience. |
| Q46423794 | Quantitative and qualitative analysis of proteins in fresh frozen plasma obtained from whole blood donations and prepared with two photochemical treatments |
| Q47826200 | Quantitative evaluation of plasma after methylene blue and white light treatment in four Chinese blood centers. |
| Q35076041 | Rationale and mechanism for the low photoinactivation rate of bacteria in plasma |
| Q37209117 | Recommendations for the transfusion of plasma and platelets |
| Q38978552 | Synthesis of a photostable near-infrared-absorbing photosensitizer for selective photodamage to cancer cells. |
| Q64111058 | The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition |
| Q50483769 | The influence of methylene blue light treatment and methylene blue removal filter on fibrinogen activity states and fibrin polymerisation indices. |
| Q24614152 | The influence of riboflavin photochemistry on plasma coagulation factors |
| Q37798900 | The status of pathogen-reduced plasma |
| Q41869417 | Thrombin Generation Capacity of Methylene Blue-Treated Plasma Prepared by the Theraflex MB Plasma System |
| Q50462990 | Thrombin generation capacity is impaired in methylene-blue treated plasma compared to normal levels in single-donor fresh-frozen plasma, a licensed solvent/detergent-treated plasma (Octaplas) and a development product (Uniplas). |
| Q36578184 | Update on pathogen reduction technology for therapeutic plasma: an overview |
| Q37166900 | Updates on pathogen inactivation of plasma using Theraflex methylene blue system |
| Q38050757 | Viral inactivation in hemotherapy: systematic review on inactivators with action on nucleic acids |
| Q41045596 | Visible light and near-infrared-responsive chromophores for drug delivery-on-demand applications |
| Q35856158 | What is happening? Are the current acceptance criteria for therapeutic plasma adequate? |
| Q50452728 | [Evolution of techniques for preparation of labile blood products (LBP): pathogen inactivation in LBP]. |
Search more.